• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

Introduction to N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone (CAS No. 1246818-79-0)

N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone is a significant compound in the field of pharmaceutical chemistry, known for its role in the development of innovative therapeutic agents. This compound, identified by its CAS number 1246818-79-0, has garnered attention due to its structural complexity and potential applications in medicinal chemistry. The molecular structure of this compound incorporates a pyridine ring, which is a common motif in many bioactive molecules, and is further modified with an N-4-(3-methoxypropoxy) group and a 3-methyl substituent. These modifications contribute to its unique pharmacological properties and make it a valuable scaffold for drug discovery.

The compound’s significance lies in its potential as a precursor or intermediate in the synthesis of more complex molecules. In recent years, there has been growing interest in the development of novel proton pump inhibitors (PPIs), which are widely used for the treatment of gastric acid-related disorders. N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone shares structural similarities with existing PPIs, such as Rabeprazole, but with additional functional groups that may enhance its pharmacokinetic profile or target specific receptors more effectively.

Recent studies have highlighted the importance of pyridine derivatives in medicinal chemistry due to their ability to interact with biological targets in a highly specific manner. The presence of the pyridine ring in N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone allows for hydrogen bonding interactions, which are crucial for the compound’s binding affinity to its intended biological targets. Additionally, the 3-methyl group and the 3-methoxypropoxy side chain contribute to the compound’s solubility and metabolic stability, making it a promising candidate for further development.

In the context of drug discovery, the synthesis and characterization of N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone have been subjects of extensive research. Advanced synthetic methodologies have been employed to optimize the yield and purity of this compound. Techniques such as multi-step organic synthesis, including cross-coupling reactions and nucleophilic substitutions, have been utilized to construct the complex molecular framework of this compound. The use of computational chemistry tools has also played a crucial role in predicting and refining the structural properties of N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone, ensuring that it meets the stringent requirements for pharmaceutical applications.

The pharmacological activity of N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone has been evaluated through various in vitro and in vivo studies. These studies have demonstrated its potential as a potent inhibitor of gastric acid secretion, similar to other PPIs. However, what sets this compound apart is its enhanced selectivity and reduced side effects, which are critical factors in patient compliance and therapeutic efficacy. The unique combination of structural features in N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone allows it to interact with specific enzymes and receptors involved in gastric acid regulation, thereby providing a more targeted approach to treating acid-related disorders.

One of the most exciting aspects of N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone is its potential for further chemical modification to enhance its pharmacological properties. Researchers are exploring various strategies to optimize its bioavailability, metabolic stability, and receptor binding affinity. For instance, modifications to the methoxypropoxy side chain could improve solubility while maintaining or enhancing activity. Additionally, exploring different substituents on the pyridine ring may lead to novel analogs with improved therapeutic profiles.

The development of new pharmaceutical agents is often hindered by issues related to patent landscapes and regulatory hurdles. However, N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone presents an opportunity to circumvent some of these challenges by serving as a novel chemical entity rather than a derivative of existing patented drugs. This approach can potentially lead to new formulations with improved efficacy and safety profiles, offering patients innovative treatment options.

As our understanding of biological pathways continues to evolve, so does our ability to design molecules that interact with these pathways more effectively. N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfone exemplifies this trend by incorporating structural elements that enhance its interaction with key biological targets. The integration of computational modeling with experimental data has enabled researchers to predict how modifications to this compound will affect its pharmacological activity, leading to faster development cycles and more efficient drug design processes.

In conclusion, N-4-(3-Methoxypropoxypropylidene) - - - - - - - - - - - - --(CAS No. 1246818-- -- -- -- -- -- -- -- -- --79-- --) represents a significant advancement in pharmaceutical chemistry. Its unique structural features make it a promising candidate for further development into novel therapeutic agents targeting gastric acid-related disorders. With ongoing research focused on optimizing its pharmacological properties and exploring new synthetic pathways, this compound holds great potential for improving patient outcomes in the future.

• 1114543-47-3(N-4-(3-Methoxypropoxy)-3-methyl-2-pyridinylmethyl Rabeprazole Sulfide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)